Registrational Phase III AMPLIFY trial: Target number of participants achieved

2026-03-10 - 13:38

SYDNEY, March 10, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III AMPLIFY trial (NCT06970847)[1] has now consented in excess of the planned number of participants following